{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T07:48:14Z","timestamp":1794383294187,"version":"4.9.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Treating recurrent multidrug resistant (MDR) urosepsis in pediatric transplant recipients can be challenging. Particularly when antibiotics fail to prevent future occurrence and the nidus is seemingly undiscoverable. While there is an increasing amount of data on phage therapy, to our knowledge, there are no published cases involving pediatric renal transplant recipients. Therefore, we present a challenging clinical case in which phage therapy was used in a pediatric renal transplant recipient who developed recurrent MDR urosepsis with an unclear source.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation:<\/jats:title>\n                    <jats:p>\n                      Our patient was a 17-year-old female who initially developed urosepsis caused by extended-spectrum \u03b2-lactamase (ESBL)\n                      <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                      , while being treated with an immunosuppressant regimen because of kidney rejection secondary to poor immunosuppression therapy compliance. She was admitted to our hospital intermittently for 4 months with 4 episodes of urosepsis caused by ESBL\n                      <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                      . She received multiple courses of antibiotics (mainly ertapenem) and underwent a fecal material transplant to eradicate her ESBL\n                      <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                      colonized gastrointestinal tract. Because of recurrent development of urosepsis after antibiotic treatment, she later underwent treatment with a phage cocktail consisting of 2 isolate-specific phages. After a prolonged antibiotic course and subsequent 3-week intravenous phage treatment, she had no ESBL\n                      <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                      in her urinary cultures for 4 years post-treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>\n                      This case highlights the challenges of treating recurrent ESBL\n                      <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                      infections in a pediatric renal transplant patient and provides evidence that phage therapy may prove useful in such cases.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000003735","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T16:00:31Z","timestamp":1665072031000},"page":"43-46","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Recurrent ESBL Escherichia coli Urosepsis in a Pediatric Renal Transplant Patient Treated With Antibiotics and Bacteriophage Therapy"],"prefix":"10.1097","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0764-3397","authenticated-orcid":false,"given":"Andrew B.","family":"Gainey","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Division of Pediatric Infectious Diseases, Prisma Health Children\u2019s Hospital\u2014Midlands, Columbia, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Daniels","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Division of Pediatric Infectious Diseases, Prisma Health Children\u2019s Hospital\u2014Midlands, Columbia, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Kathryn","family":"Burch","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Infectious Diseases, Prisma Health Children\u2019s Hospital\u2014Midlands, Columbia, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hawn","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of General and Hospital Pediatrics, Prisma Health Children\u2019s Hospital\u2014Midlands, Columbia, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Fackler","sequence":"additional","affiliation":[{"name":"Adaptive Phage Therapeutics, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswajit","family":"Biswas","sequence":"additional","affiliation":[{"name":"Department of Genomics & Bioinformatics, Biological Defense Research Directorate, Naval Medical Research Center, Frederick, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Brownstein","sequence":"additional","affiliation":[{"name":"Adaptive Phage Therapeutics, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"R1-20260716","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3390\/diagnostics11081456","article-title":"A current review of the etiology, clinical features, and diagnosis of urinary tract infection in renal transplant patients.","volume":"11","author":"Su\u00e1rez Fern\u00e1ndez","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"R2-20260716","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40620-019-00585-3","article-title":"Updates on urinary tract infections in kidney transplantation.","volume":"32","author":"Fiorentino","year":"2019","journal-title":"J Nephrol"},{"key":"R3-20260716","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1399-3062.2012.00744.x","article-title":"Bacterial urinary tract infection after solid organ transplantation in the RESITRA cohort.","volume":"14","author":"Vidal","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"R4-20260716","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jgar.2020.10.013","article-title":"Institutional protocol adherence in the incidence of recurrent urinary tract infection after kidney transplantation.","volume":"23","author":"Freire","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"R5-20260716","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.3390\/antibiotics10121496","article-title":"Potential solutions using bacteriophages against antimicrobial resistant bacteria.","volume":"10","author":"Rahimi-Midani","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"R7-20260716","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1473-3099(20)30330-3","article-title":"Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial.","volume":"21","author":"Leitner","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R8-20260716","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/22221751.2020.1747950","article-title":"Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiella pneumoniae.","volume":"9","author":"Bao","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"R9-20260716","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3390\/v13102049","article-title":"Phage therapy related microbial succession associated with successful clinical outcome for a recurrent urinary tract infection.","volume":"13","author":"Terwilliger","year":"2021","journal-title":"Viruses"},{"key":"R10-20260716","doi-asserted-by":"crossref","first-page":"e01281","DOI":"10.1128\/AAC.01281-19","article-title":"A dutch case report of successful treatment of chronic relapsing urinary tract infection with bacteriophages in a renal transplant patient.","volume":"64","author":"Kuipers","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20260716","doi-asserted-by":"crossref","first-page":"e13391","DOI":"10.1111\/tid.13391","article-title":"Treatment of recurrent urinary tract infections in a 60-year-old kidney transplant recipient. The use of phage therapy.","volume":"23","author":"Rostkowska","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"R13-20260716","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/ppul.24945","article-title":"Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient.","volume":"55","author":"Gainey","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"R14-20260716","doi-asserted-by":"crossref","first-page":"e01652","DOI":"10.1128\/mBio.01652-19","article-title":"Resistance evolution against phage combinations depends on the timing and order of exposure.","volume":"10","author":"Wright","year":"2019","journal-title":"mBio"},{"key":"R15-20260716","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11538-020-00751-w","article-title":"Optimizing the timing and composition of therapeutic phage cocktails: a control-theoretic approach.","volume":"82","author":"Li","year":"2020","journal-title":"Bull Math Biol"},{"key":"R16-20260716","doi-asserted-by":"crossref","first-page":"e13936","DOI":"10.15252\/emmm.202113936","article-title":"Bacterial lysis, autophagy and innate immune responses during adjunctive phage therapy in a child.","volume":"13","author":"Khatami","year":"2021","journal-title":"EMBO Mol Med"},{"key":"R17-20260716","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/med.21572","article-title":"Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review.","volume":"39","author":"D\u0105browska","year":"2019","journal-title":"Med Res Rev"},{"key":"R18-20260716","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2217\/fvl-2019-0110","article-title":"Phage penetration of eukaryotic cells: practical implications.","volume":"14","author":"\u017baczek","year":"2019","journal-title":"Future Virol"},{"key":"R19-20260716","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.3390\/microorganisms8111802","article-title":"Phage prevalence in the human urinary tract-current knowledge and therapeutic implications.","volume":"8","author":"\u017baczek","year":"2020","journal-title":"Microorganisms"},{"key":"R20-20260716","first-page":"ciac453","article-title":"Phage therapy of mycobacterium infections: compassionate-use of phages in twenty patients with drug-resistant mycobacterial disease [published online ahead of print, 2022 Jun 9].","author":"Dedrick","year":"2022","journal-title":"Clin Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003735","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:02:20Z","timestamp":1784224940000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003735","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,6]]}}}